|
|
|
Volumn 119, Issue 1237, 2006, Pages
|
|
Roche responds to the 'Herceptin or deception' article.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
BREAST TUMOR;
COST BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG CONTROL;
DRUG SCREENING;
ECONOMICS;
FEMALE;
HUMAN;
METHODOLOGY;
NEW ZEALAND;
NOTE;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
COST-BENEFIT ANALYSIS;
DRUG AND NARCOTIC CONTROL;
DRUG APPROVAL;
DRUG EVALUATION;
FEMALE;
HUMANS;
NEW ZEALAND;
TREATMENT OUTCOME;
|
|
EID: 33746916474
PISSN: None
EISSN: 11758716
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
